Navigation Links
FLAG Therapeutics and Duquesne University Announce Exclusive Worldwide Licensing Agreement for Novel, Dual-action Targeted Oncology Compounds
Date:12/4/2013

RALEIGH, N.C. and PITTSBURGH, Dec. 4, 2013 /PRNewswire/ -- FLAG Therapeutics Inc. and Duquesne University today announced an exclusive worldwide licensing agreement for two novel classes of small molecule, water-soluble drugs designed to target and destroy cancer cells: anti-angiogenic/anti-tubulin (AA/AT) compounds and folate-targeted anti-cancer (FTAC) compounds. The agreement represents one of the largest licensing ventures in Duquesne's history and encompasses the career portfolio of renowned cancer researcher and Duquesne professor Dr. Aleem Gangjee.  A vast library of compounds and an intellectual property portfolio protected by over 50 US and international patents and patent applications are included in the deal.

(Logo: http://photos.prnewswire.com/prnh/20131204/CL26584LOGO )

The AA/AT compounds included in the agreement are the first compounds ever to combine the dual-action of the two major classes of anti-cancer drugs into a single molecule.  An emerging understanding of tumor vasculature highlights the importance of simultaneously attacking tumors with both drugs, but current treatment combination regimens often miss the window of opportunity due to different dosing schedules and pharmacokinetics.  FLAG Therapeutics' dual acting AA/AT compounds deliver a simultaneous anti-angiogenic and anti-tubulin assault on the tumor.  By attacking the tumor when it is most vulnerable, FLAG hopes to increase drug efficacy while decreasing the potency of the anti-tubulin activity for improved tolerability.  In addition, FLAG's AA/AT compounds are designed to circumvent the two major mechanisms of drug resistance (P-glycoprotein (PGP) and β-III tubulin overexpression) that limit the utility of current therapies.

The second class of drugs, FTAC compounds, is designed to selectively bind to sites found almost exclusively on certain cancer cells and interrupt cell multiplication.  Traditional anti-cancer drugs indiscriminately kill cells as they divide, the result being that while rapidly dividing cancer cells bear the brunt of the toxic activity, fast dividing normal cells (blood cells, mucosal linings and hair follicles) incur collateral damage.  FLAG's FTAC compounds are engineered to specifically and selectively bind to targeted cancer cells to avoid harming healthy cells.

Frank Sorgi, Ph.D., president and chief executive officer of FLAG Therapeutics, stated, "I am pleased to partner with Duquesne University to further develop AA/AT and FTAC compounds.  Dr. Gangjee is a highly respected researcher, and FLAG is honored to be in the position to advance his discoveries from the bench, into the clinic, and ultimately to individuals in need of new cancer therapeutic treatment options."  Dr. Sorgi continued, "We already have identified lead clinical candidates, each supported with encouraging comparative in vivo data versus current therapies, and we look forward to rapidly advancing these compounds into clinical trials."

Dr. Alan Seadler, associate provost for research and technology at Duquesne, commented, "We feel this licensing agreement provides the best possible strategy to develop the discoveries of Dr. Gangjee and hopefully provide life-saving drugs to people battling cancer.  We are particularly pleased to be working with FLAG Therapeutics to reach this goal."

About FLAG Therapeutics

FLAG Therapeutics Inc., headquartered in Raleigh, North Carolina, is an early-stage oncology company focused on the development of therapies based on two novel classes of small molecule, water-soluble drugs.  In vivo studies suggest that both classes of compounds, anti-angiogenic/anti-tubulin (AA/AT) compounds and folate-targeted anti-cancer (FTAC) compounds, hold the potential to treat multiple cancer types with greater safety and efficacy than conventional therapies.  FLAG Therapeutics has obtained exclusive worldwide rights to these compounds from Duquesne University.  To learn more about FLAG Therapeutics, please visit www.flagtherapeutics.com. Information on FLAG Therapeutics' website is not incorporated by reference into this press release.

About Duquesne University

Founded in 1878, Duquesne is consistently ranked among the nation's top Catholic research universities for its award-winning faculty and tradition of academic excellence.  Duquesne, a campus of more than 10,000 graduate and undergraduate students, has been nationally recognized for its academic programs, community service and commitment to sustainability. www.duq.edu. Contacts: Duquesne University

FLAG Therapeutics, Inc.Karen Ferrick-Roman

Frank L. Sorgi, PhDMedia Relations Manager

President and CEO 412-396-1154

919-294-6472 412-736-1877 (cell)

frank.sorgi@FlagTherapeutics.com ferrickromank@duq.edu
'/>"/>

SOURCE FLAG Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Initial Data from Lightlake Therapeutics Joint Clinical Trial with NIDA Shows Nasal Delivery of Naloxone for Opioid Overdose as a Promising Treatment
2. Dual Chamber Syringes & Injectors. Devices, Therapeutics, Markets and Forecasts
3. Updated Presentation Time: Mirati Therapeutics to Present at the 25th Annual Piper Jaffray Healthcare Conference
4. Nora Therapeutics to Present at the Oppenheimer 24th Annual Healthcare Conference
5. Lorus Therapeutics Completes New Executive Management Team
6. Orexigen Therapeutics to Present at the 25th Annual Piper Jaffray Healthcare Conference
7. Halozyme Therapeutics To Present At The Piper Jaffray Healthcare Conference
8. Cardinal Health, Prime Therapeutics Renew Primary Distribution Agreement
9. Potential Acquisitions and Stock Price Updates - Research Report on BioMarin, Covidien, United Therapeutics, Brookdale, and Seattle Genetics
10. Mast Therapeutics To Present At The 25th Annual Piper Jaffray Healthcare Conference On December 3
11. Northwest Biotherapeutics Completes Public Offering Of Common Stock And Warrants; Underwriter Exercises Full Over-Allotment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/4/2017)... OBP Medical , a leading ... today announced regulatory approval from Brazil,s ... Nacional de Vigilância Sanitária (ANVISA)) to market ... with integrated LED light source and smoke evacuation ... of a tissue pocket or cavity during surgical ...
(Date:10/2/2017)... INDIANAPOLIS , Oct. 2, 2017  Eli Lilly ... its financial results for the third quarter of 2017 ... a conference call on that day with the investment ... performance. The conference call will begin at ... public can access a live webcast of the conference ...
(Date:10/2/2017)... 2017 Halo Labs announces the European launch of their ... HORIZON at MIBio 2017 in Cambridge, U.K ... matter in biopharmaceutical samples with unprecedented speed and sensitivity while using ... Backgrounded Membrane Imaging. ... subvisible particle analysis system ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... ... Hannah Randall, PharmD ‘17, and Jennifer Huggins, PharmD ’17, along with clinical ... the primary prevention of cardiovascular diseases during the 15th Annual Women’s Health ...
(Date:10/13/2017)... BASKING RIDGE, N.J. (PRWEB) , ... October 13, 2017 , ... ... second annual Holly Day Market. Featuring a collection of specialty vendors and unique items ... myriad of personalized and quality-focused health and wellness services offered by the VNA. ...
(Date:10/13/2017)... ... 2017 , ... Talented host, actor Rob Lowe, is introducing ... new episode of "Success Files," which is an award-winning educational program broadcasted on ... subject in-depth with passion and integrity. , Sciatica occurs when the sciatic nerve ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare ... program management, will showcase a range of technology and learning solutions at the ... Convention and Expo to be held October 14–18, 2017 at the Mandalay Bay ...
(Date:10/12/2017)... CITY, Fla. (PRWEB) , ... October 12, 2017 , ... ... cold therapy products, announced today the introduction of an innovative new design of the ... multipurpose pad so you get maximum comfort while controlling your pain while using cold ...
Breaking Medicine News(10 mins):